Short answer: In the Baqsimi label's adult trials of one 3 mg nasal dose, nausea affected 26%, headache 18%, vomiting 15% and nose or throat irritation 12%. When asked directly, 59% reported watery eyes and 43% nasal congestion. In children 4 to under 17, vomiting affected 31% and headache 25%. Baqsimi has no boxed warning; it is not used with pheochromocytoma or insulinoma.
What Baqsimi is approved for: Baqsimi is approved to treat severe low blood sugar (severe hypoglycemia) in adults and children aged 1 year and older with diabetes (section 1).
Source
BAQSIMI (glucagon) nasal powder, prescribing information, Patient Information and Instructions for Use. Amphastar Pharmaceuticals. DailyMed, version published August 11, 2025. DailyMed setid f1f5df9b-872f-44e5-a18f-f0b68e7e9254
No. The current Baqsimi label has no boxed warning.
These are the label's own numbers from the Adverse Reactions section. Where the label compares with placebo (a dummy treatment), both columns are shown, so you can see how much more often a reaction happened on Baqsimi.
| Adverse reaction | BAQSIMI 3 mg, % (N=153) |
|---|---|
| Nausea | 26 |
| Headache | 18 |
| Vomiting | 15 |
| Upper respiratory tract irritation | 12 |
Single 3 mg nasal dose. The studies compared Baqsimi with 1 mg intramuscular glucagon, but the table shows only the Baqsimi column. Upper respiratory tract irritation means runny nose, nasal discomfort, nasal congestion, cough and nosebleed.
| Adverse reaction | BAQSIMI 3 mg, % (n=153) |
|---|---|
| Watery eyes | 59 |
| Nasal congestion | 43 |
| Nasal itching | 39 |
| Runny nose | 35 |
| Redness of eyes | 25 |
| Itchy eyes | 22 |
| Sneezing | 20 |
| Itching of throat | 12 |
| Itching of ears | 3 |
Asked on a questionnaire; counts any increase in symptom severity from before the dose.
| Adverse reaction | BAQSIMI 3 mg, % (n=36) |
|---|---|
| Vomiting | 31 |
| Headache | 25 |
| Nausea | 17 |
| Upper respiratory tract irritation | 17 |
Upper respiratory tract irritation means nasal discomfort, nasal congestion and sneezing.
| Adverse reaction | BAQSIMI 3 mg, % (n=36) |
|---|---|
| Watery eyes | 47 |
| Nasal congestion | 42 |
| Nasal itching | 28 |
| Runny nose | 25 |
| Sneezing | 19 |
| Itchy eyes | 17 |
| Redness of eyes | 14 |
| Itching of throat | 3 |
| Itching of ears | 3 |
In 7 children aged 1 to under 4 with type 1 diabetes given one 3 mg dose, the safety profile was comparable to adults and older children.
Other reactions seen across trials: change in taste, itching, fast heart rate, high blood pressure, and more nose and throat irritation (nasal itching, throat irritation and a changed sense of smell).
The Warnings and Precautions part of the label lists these. Each line gives the label's heading and what it means in plain words.
Who should not use it. Baqsimi is not used by people with pheochromocytoma (an adrenal gland tumor) or insulinoma (a pancreas tumor), or who have had an allergic reaction to glucagon or its ingredients.
Blood pressure spike with pheochromocytoma. Glucagon can make this adrenal tumor release hormones that raise blood pressure sharply.
Low blood sugar with insulinoma. In people with this pancreas tumor, glucagon can first raise blood sugar and then trigger too much insulin, causing low blood sugar. Glucose is given by mouth or vein if that happens.
Serious allergic reactions. Serious allergic reactions, including rash and in some cases anaphylactic shock with breathing trouble and low blood pressure, have been reported with glucagon. Baqsimi is stopped and medical help sought right away.
May not work with low liver glycogen. People with low glycogen stores in the liver, such as with starvation, adrenal insufficiency or long-lasting low blood sugar, may not respond to Baqsimi.
From the Patient Information that comes with Baqsimi:
Dose Track has a side-effect log. Each entry records the symptom, a severity (none, mild, moderate, severe or life-threatening), the date and an optional note, and can be tied to a specific dose or logged on its own. The history screen shows what you logged over time, which makes it easier to tell your prescriber when a reaction started and whether it is easing. The app records what you enter; it does not judge whether a symptom is serious. For anything on the label's call-your-doctor list, call your doctor.
This page is what the FDA label says, in plain words. It is not medical advice. Follow your prescriber, and ask them or your pharmacist about anything here.